Crystal structure of phosphodiesterase 4D and inhibitor complex1

[1]  A. Robichaud,et al.  The next generation of PDE4 inhibitors. , 2001, Current opinion in chemical biology.

[2]  T. Kronbach,et al.  Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. , 2001, Cellular signalling.

[3]  Y. Zhao,et al.  Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. , 2000, Science.

[4]  A. Govindarajan,et al.  Conformational difference between PDE4 apoenzyme and holoenzyme. , 2000, Biochemistry.

[5]  C. Page,et al.  Phosphodiesterases: the journey towards therapeutics. , 2000, Trends in pharmacological sciences.

[6]  E. Fauman,et al.  Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity. , 2000, Molecular pharmacology.

[7]  J. Beavo,et al.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Corbin,et al.  Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)* , 1999, The Journal of Biological Chemistry.

[9]  C. Hulme,et al.  Benzofuran based PDE4 inhibitors. , 1999, Bioorganic & medicinal chemistry.

[10]  J. Colicelli,et al.  Identification of Inhibitor Specificity Determinants in a Mammalian Phosphodiesterase* , 1999, The Journal of Biological Chemistry.

[11]  K. Kuma,et al.  Ancient gene duplication and domain shuffling in the animal cyclic nucleotide phosphodiesterase family 1 , 1998, FEBS letters.

[12]  J. Mason,et al.  Novel cyclic compounds as potent phosphodiesterase 4 inhibitors. , 1998, Journal of medicinal chemistry.

[13]  S. Christensen,et al.  1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. , 1998, Journal of medicinal chemistry.

[14]  P. Reinemer,et al.  Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. , 1995, Journal of molecular biology.

[15]  M. Conti,et al.  Characterization of a hormone-inducible, high affinity adenosine 3'-5'-cyclic monophosphate phosphodiesterase from the rat Sertoli cell. , 1995, Biochemistry.

[16]  M. Ashton,et al.  Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. , 1994, Journal of medicinal chemistry.

[17]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[18]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[19]  D. Ukena,et al.  Zardaverine as a selective inhibitor of phosphodiesterase isozymes. , 1991, Biochemical pharmacology.

[20]  C. Wermuth,et al.  Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. , 1989, Journal of medicinal chemistry.

[21]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[22]  B. Sanwal,et al.  The cyclic adenosine monophosphate phosphodiesterases of myoblasts, fibroblasts, and their somatic cell hybrids. , 1979, Canadian journal of biochemistry.

[23]  J. Corbin,et al.  Cyclic nucleotide phosphodiesterases: relating structure and function. , 2001, Progress in nucleic acid research and molecular biology.

[24]  M. Houslay,et al.  PDE4 cAMP-specific phosphodiesterases. , 2001, Progress in nucleic acid research and molecular biology.

[25]  M. A. Rould.  [26] Screening for heavy-atom derivatives and obtaining accurate isomorphous differences. , 1997, Methods in enzymology.